意大利外阴鳞状细胞癌女性患者的患病率及治愈指标：一项基于人群的研究。

Prevalence and indicators of cure of Italian women with vulvar squamous cell carcinoma: A population-based study.

作者信息

Bucchi Lauro, Giudici Fabiola, Toffolutti Federica, De Paoli Angela, Mancini Silvia, Preti Mario, Gatta Gemma, Ferretti Stefano, Crocetti Emanuele, Fiore Anna Rita, Bidoli Ettore, Caldarella Adele, Falcini Fabio, Gili Alessio, Cuccaro Francesco, Gambino Maria Letizia, Casella Claudia, Cavallo Rossella, Ferrante Margherita, Migliore Enrica, Carrozzi Giuliano, Musolino Antonino, Mazzucco Walter, Gasparotti Cinzia, Fusco Mario, Ballotari Paola, Sampietro Giuseppe, Mangone Lucia, Mantovani William, Cascone Giuseppe, Mian Michael, Manzoni Federica, Pesce Maria Teresa, Galasso Rocco, Bella Francesca, Seghini Pietro, Fanetti Anna Clara, Piras Daniela, Pinna Pasquala, Serraino Diego, Guzzinati Stefano, Dal Maso Luigino

机构信息

Emilia-Romagna Cancer Registry, Romagna Unit, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) Dino Amadori, Meldola, Forlì, Italy.

Cancer Epidemiology Unit, Centro di Riferimento Oncologico di Aviano (CRO) IRCCS, Aviano, Italy.

出版信息

Eur J Surg Oncol. 2025 Apr;51(4):108707. doi: 10.1016/j.ejso.2024.108707. Epub 2024 Sep 26.

DOI:10.1016/j.ejso.2024.108707

PMID:39467724

Abstract

OBJECTIVE

Five-year net survival and conditional survival from vulvar squamous cell carcinoma (VSCC) patients in Italy have shown no progress during the past three decades. This study aims to estimate the complete prevalence and multiple indicators of cure.

METHODS

Observed prevalence was estimated using 31 Italian cancer registries covering 47 % of Italian women. A subset of 22 cancer registries was used to estimate model-based long-term survival and indicators of cure, i.e., complete prevalence, cure fraction (CF), time to cure (TTC), proportion of 'already cured' patients, and cure prevalence.

RESULTS

In 2018, VSCC patients alive in Italy (complete prevalence) were 6620 or 22 per 100,000 women. The cure fraction (the proportion of newly diagnosed patients who will not die of VSCC) did not change between 2000 and 2010 both for all patients (32 %) and in each age group. The time to cure (5-year conditional net survival >95 %) was 11 years for patients aged ≥44 years, but excess mortality remained for >15 years in the other age groups. This led to a negligible (5 %) proportion of 'already cured' patients (living longer than time to cure). The proportion of patients alive <2 years (21 %) was the same as that of patients surviving ≥15 years. The cure prevalence (patients who will not die of VSCC) was 64 %. A considerable proportion of patients will not be cured even among those who survived ≥5 years.

CONCLUSION

There is an urgent need to reshape the current vulvar care model in Italy.

摘要

目的

在过去三十年中，意大利外阴鳞状细胞癌（VSCC）患者的五年净生存率和条件生存率并无进展。本研究旨在估计完全患病率和多种治愈指标。

方法

使用覆盖47%意大利女性的31个意大利癌症登记处来估计观察到的患病率。使用22个癌症登记处的子集来估计基于模型的长期生存率和治愈指标，即完全患病率、治愈分数（CF）、治愈时间（TTC）、“已治愈”患者比例和治愈患病率。

结果

2018年，意大利存活的VSCC患者（完全患病率）为6620例，即每10万名女性中有22例。2000年至2010年期间，所有患者（32%）以及各年龄组中，治愈分数（新诊断患者中不会死于VSCC的比例）均未改变。对于年龄≥44岁的患者，治愈时间（5年条件净生存率>95%）为11年，但其他年龄组中超过15年仍存在额外死亡率。这导致“已治愈”患者（存活时间超过治愈时间）的比例可忽略不计（5%）。存活<2年的患者比例（21%）与存活≥15年的患者比例相同。治愈患病率（不会死于VSCC的患者）为64%。即使在存活≥5年的患者中，也有相当一部分患者无法治愈。